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Background: MicroRNAs (miRNAs) are small, non-coding RNA molecules involved in post-transcriptional gene
regulation and have recently been shown to play a role in cancer metastasis. In solid tumors, especially breast
cancer, alterations in miRNA expression contribute to cancer pathogenesis, including metastasis. Considering
the emerging role of miRNAs in metastasis, the identification of predictive markers is necessary to further the
understanding of stage-specific breast cancer development. This is a retrospective analysis that aimed to identify
molecular biomarkers related to distant breast cancer metastasis development.
Methods: A retrospective case cohort study was performed in 64 breast cancer patients treated during the period
from 1998–2001. The case group (n = 29) consisted of patients with a poor prognosis who presented with breast
cancer recurrence or metastasis during follow up. The control group (n = 35) consisted of patients with a good
prognosis who did not develop breast cancer recurrence or metastasis. These patient groups were stratified according
to TNM clinical stage (CS) I, II and III, and the main clinical features of the patients were homogeneous. MicroRNA
profiling was performed and biomarkers related to metastatic were identified independent of clinical stage. Finally, a
hazard risk analysis of these biomarkers was performed to evaluate their relation to metastatic potential.
Results: MiRNA expression profiling identified several miRNAs that were both specific and shared across all clinical
stages (p≤ 0.05). Among these, we identified miRNAs previously associated with cell motility (let-7 family) and distant
metastasis (hsa-miR-21). In addition, hsa-miR-494 and hsa-miR-21 were deregulated in metastatic cases of CSI and CSII.
Furthermore, metastatic miRNAs shared across all clinical stages did not present high sensitivity and specificity when
compared to specific-CS miRNAs. Between them, hsa-miR-183 was the most significative of CSII, which miRNAs
combination for CSII (hsa-miR-494, hsa-miR-183 and hsa-miR-21) was significant and were a more effective risk
marker compared to the single miRNAs.
Conclusions: Women with metastatic breast cancer, especially CSII, presented up-regulated levels of miR-183,
miR-494 and miR-21, which were associated with a poor prognosis. These miRNAs therefore represent new risk
biomarkers of breast cancer metastasis and may be useful for future targeted therapies.
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Breast cancer is the most frequent tumor after skin malig-
nancies, representing the second most common cancer-
related mortality in women [1]. Although TNM staging
provides important clinical prognostic information,
mammary tumors are known to be biologically hetero-
geneous with regard to therapeutic responses as well as
molecular profiling [2,3]. For example, these tumors can
be characterized as luminal A, luminal B, basal-like,
human epidermal growth factor receptor 2 (HER-2)-
overexpressing or claudin-low [4], and this profiling
provides additional molecular prognostic markers. In
addition, a recent study demonstrated that the micro-
RNA expression signature appears to provide a better
characterization of cancer subtypes than transcriptional
profiles and may therefore represent a new classification
system for breast cancer [5].
MicroRNAs (miRNAs) are small, non-coding RNAs of
19–25 nt that control a wide array of physiological and
pathological processes by modulating the expression of
their cognate target genes through cleaving mRNA mol-
ecules or inhibiting their translation [6]. Most cancer
tissues are archived as formalin-fixed, paraffin-embedded
(FFPE) samples, and microRNAs are promising bio-
markers because they are a stable form of RNA. Moreover,
recent studies have shown a good correlation between
microRNA samples from frozen and FFPE sections [7,8].
MiRNAs regulate key biological processes such as
development, differentiation, stress response, apoptosis
and proliferation [9-11] and are consequently implicated
in several diseases including cancer [12-14].
Iorio et al. [13] demonstrated the influence of miRNA
deregulation in the development of breast cancer in
several tissues and lineages, and other studies have
correlated miRNA profiles with mRNA subtypes, par-
ticularly with regard to estrogen receptor (ER), progester-
one receptor (PR) and HER2 status [4,14]. In addition,
specific miRNAs have been associated with steps of the
metastasis cascade, such as micrometastasis, local inva-
sion, intravasation and metastatic colonization [15].
However, in practice, few miRNA expression signatures
have been shown to correlate with breast cancer metas-
tasis, and although the epithelial to mesenchymal tran-
sition (EMT) is a critical event for metastasis from
carcinomas, few studies evaluating miRNAs during
EMT have been performed in breast cancer [16,17]. In
breast cancer, one example is miR-183, which have been
associated with migration and invasion [18,19]. How-
ever, the results regard to miR-183 is controversial. In a
recent study of meta-analysis, comparing cancer tissues
with controls of several tumor types, this miRNA pre-
sented inconsistent regulation in breast cancer [20].
However, miR-183 expression has not been evaluated in
a metastatic breast cancer context.The main goal of this study was to identify miRNA
biomarkers of breast cancer metastasis. Using a collection
of FFPE samples, we selected clinically homogeneous sam-
ples, and we paired metastatic and non-metastatic patients
according to tumor grade. Using this strategy, we detected,
with improved precision, miRNA biomarkers that could
characterize metastasis irrespective of clinical staging as
well as stage-specific biomarkers.
Methods
Study population
A retrospective case cohort study [21] was performed in
782 patients with invasive breast cancer (ductal or lobular),
without metastasis at diagnosis (clinical stage I, II and III)
who had previously received treatment at Barretos Cancer
Hospital between 1998 and 2001. In this study, the case
group consisted of patients with a poor prognosis who
developed breast cancer recurrence and/or metastasis dur-
ing a follow up of ten years. The rate of cases with metasta-
sis according each clinical stage was: 12.8% to CSI (total of
117), 25% to CSII (total of 352), 51% to CSIII (total of 313).
The control group consisted of a random sample of
patients who did not develop breast cancer recurrence
and/or metastasis and had a good prognosis. The control
group presented the same apparent risk and length of
follow up period as the case group. The rate of cases
with non-metastasis according each clinical stage was:
87.2% to CSI (117 total cases), 75% to CSII (total cases
352), 49% (313 total cases).
The groups also had a similar distribution of clinical
staging (CS) according to TNM classification (TNM 7th
edition) [2]. All patients were treated at the same institu-
tion with same treatment protocol and received regular
follow-up assessments at the Department of Mastology
and Reconstructive Surgery at Barretos Cancer Hospital,
Barretos, Sao Paulo, Brazil. Patients were excluded if they
had a second primary tumor, an insufficient blocked
tumor or the absence of high-quality miRNA for extrac-
tion. This study was approved by Barretos Cancer Hospital
ethical committee, (protocol n°362/2010).
Pathologic evaluation
The same pathologist reviewed all of the medical
records. Immunohistochemistry evaluation was per-
formed in all cases, including the assessment of ER and
PR status and the expression of Ki-67, Her2 and cyto-
keratin 5/6. ER status was evaluated using the Pathway
anti-Her-2 790–2991 monoclonal antibody (Ventana
Medical Systems, Roche Diagnosis, Tucson, Arizona
85755, USA) at a dilution of 1:200.
PR status was evaluated using the Rabbit monoclonal
antibody clone clone SP1 at a dilution of 1:600. Ki-67
expression was evaluated using the monoclonal antibody
MIB-1 (Dako, Sao Paulo, Brazil) at a dilution of 1:200.
Table 1 Clinical and pathological features of the patient
groups according to Fisher’s test
Recurrence Absent Present Total p value
Selected variables before pairing
CS-TNM EC I 9 (69%) 4 (31%) 13 0.385
EC II 13 (56%) 10 (43%) 23
EC III 13 (46%) 15 (54%) 28
CS-T (TNM) T1 15 (56%) 12 (44%) 27 0.742
T2 10 (56%) 8 (44%) 18
T3 6 (67%) 3 (33%) 9
T4 4 (40%) 6 (60%) 10
CS-N (TNM) N0 17 (68%) 8 (32%) 25 0.378
N1 9 (47%) 10 (53%) 19
N2 5 (50%) 5 (50%) 10
N3 4 (40%) 6 (60%) 10
Categorical variables observed after pairing
Histology Ductal 30 (61%) 19 (39%) 49 0.078
Lobular 5 (33%) 10 (67%) 15
ER ER + 21 (62%) 13 (38%) 34 0.226
ER - 14 (47%) 16 (53%) 30
PR PR + 16 (76%) 5 (24%) 21 0.018
PR - 19 (44%) 24 (56%) 43
Her2 Her2 + 5 (38%) 8 (62%) 13 0.158
Her2 - 30 (59%) 21 (41%) 51
Molecular Luminal 23 (64%) 13 (36%) 36 0.265
Subtypes Basal like 9 (45%) 11 (55%) 20
Her2 3 (38%) 5 (62%) 8
ER = estrogen receptor; PR = progesterone receptor.
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clone 4B5 (Ventana Medical Systems, Roche Diagnosis,
Tucson, Arizona 85755, USA) at a 1:2,000 dilution.
The cytokeratin 5/6 status was evaluated using the
mouse monoclonal D5/16B4 (Dako, Sao Paulo, Brazil) at
a 1:100 dilution. ER and PR expression was considered
positive when 1% of tumor cells showed positive staining.
The Ki-67 cutoff value was 14%. For Her2 semi-
quantitative immunohistochemistry (2+ and 3+), the
DISH test was performed using Her2 Dako K5331
(Dako, Sao Paulo, Brazil). Basal-like tumors were char-
acterized according to triple-negative receptor status
and positive C5/6 status. We applied immunohisto-
chemistry molecular characteristic subgroups based on
previous reports [22,23].
Patients and case selection
During the paring we considered a case-cohort ratio 1:1.
After using the inclusion and exclusion criteria, 64
patients were selected including 29 in the case group
and 35 in the control group. Ductal invasive carcinoma
represented 76.6% of the group histology. The average
patient age was 53.1 years (29–95), and the average
tumor size was 3.1 cm (1.0-8.5 cm).
The groups were homogeneous, and there were no differ-
ences between the variables selected prior to pairing. Table 1
summarizes the main patient features, with the associated
p-values from the Fisher test using SPSS software. Using a
t-test for independent variables, there were no differences
between groups related to tumor size (mean 3.24 × 3.04;
p = 0.592) or age (mean 49.1 × 56.4; p = 0.07). After pairing
and pathologic classification, we observed that only the PR
status differed between the groups (Table 1).
The mean group follow-up duration was 82.0 months
(5.1-162 months); excluding the case group, this period
was 120.6 months. At the end of the study, 25/29
patients in the case group had died of cancer, while the
others remained alive with tumor recurrence.
Total RNA isolation from FFPE sections
FFPE samples were submitted to a total RNA isolation
protocol using the Recover All TM Total Nucleic Acid
Isolation kit (Life Technologies). The samples were ini-
tially treated with xylene, followed by double washing
with absolute ethanol and proteinase K treatment at 50°C
for 3 hours. Quantification was performed using a nano-
drop ND-1000 spectrophotometer (NanoDrop Products,
Wilmington, DE), and RNA quality was assessed using an
Agilent Small RNA chip with a Bioanalyzer device (Agilent
Technologies).
miRNA microarrays
The Agilent Human miRNA Microarray (8 × 15K -
G4471A, Agilent Technologies) was used in all samplesfrom FFPE sections. Additional microarrays of frozen
samples were performed in comparison to those ob-
tained from FFPE, as quality control (Additional file 1:
Figure S2). A total of 100 ng of total RNA was hybrid-
ized using miRNA complete labeling and the Hyb Kit
(Agilent Technologies), according to the manufacturer’s
instructions. The reactions followed a 2-step preparation,
represented by dephosphorylation and denaturation of the
total RNA incorporated with Cy3 fluorochrome by the T4
ligase. The next steps included standard washing proce-
dures and hybridization with microarrays slides. The
images were scanned using an Agilent DNA microarray
scanner with SureScan technology (Agilent Technologies).
miRNA microarray data analysis
The raw data were obtained using Feature Extraction
software v.11.0 (Agilent Technologies) and submitted to
R environment v. 2.15.0 [24] for further analysis. The
median signals (gMedianSignal and gBGMedianSignal)
were used. Following background subtraction and log2
scale transformation, normalization was performed using
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Differentially expressed microRNAs were obtained by
rank product analysis using the RankProd package
[26], considering p-values and positive false predic-
tions (pfp) ≤ 0.05. The rank product analyses were
separated according to clinical staging between groups
(CSI-CSIM, CSII-CSIIM, CSIII-CSIIIM). Differentially
expressed miRNAs were further ranked according to
sensitivity and specificity to determine the best candi-
dates between non-metastatic patients and metastatic
patients in a stage-specific manner. Sensitivity and
specificity are defined as the number of true positive
decisions/the number of actually positive cases and the
number of true negative decisions/the number of actu-
ally negative cases. The area under the ROC curve
(AUC) is a measure for overall performance, which can
be interpreted as the average value of sensitivity for all
possible values of specificity [27]. The criteria for bio-
marker selection included sensitivity and specificity
values ≥ 80%, as determined using the ROCR package
[28]. Differentially expressed microRNAs were clus-
tered by Euclidian distance and average linkage using
the heatmap.2 function of the gplots package [29].
Real-time PCR and disease-free survival analysis
The criteria for miRNA selection for further RT-qPCR
confirmation, and further analysis, was the high signifi-
cance (pvalue and pfp) of the miRNA, biological rele-
vance after literature search and which is present in (1)
both groups and (2) at least 1 miRNA specific of each
metastatic group compared to their specific primary
patient of the same CS. We performed a Venn diagrams’
to represent this selection, using gplots package [29].
Taqman microRNA assays (Life Technologies, Foster
City, CA, USA) were used to confirm the microarray
data. In brief, these reactions consist of reverse tran-
scription with miRNA-specific primers in a real-time
PCR reaction with Taqman probes. The reverse tran-
scriptase reactions used in this study contained 10 ng of
total RNA and utilized the High Capacity cDNA Reverse
Transcription Kit (Life Technologies), according to the
manufacturer’s instructions, in a thermocycler (Eppendorf).
All real-time PCR reactions were performed in tripli-
cate in a 7900 HT Fast Real-time PCR System (Applied
Biosystems USA). All analysis procedures were per-
formed in R environment. The normalization step was
performed according to the 2-ΔΔCt method [30]. Cycle
threshold (Ct) values from selected miRNA targets
were subtracted from the Ct values of the endogenous
small noncoding RNA control RNU48 (Control miRNA
Assay, Applied Biosystems, Foster City, CA, USA). A
subsequent ΔΔCt value was calculated by subtracting
metastatic ΔCt values from non-metastatic ones. The
data cutoff for modulation (up/down) in each patientwas estimated according to the threshold obtained after
receiver operating characteristic (ROC) curve analysis
using the ROCR package. To assess the combination of
biomarkers, a general logistic model (glm) was performed
prior to ROC analysis. MiRNA modulation (up/down) was
used, and data from the first clinical evaluation until
recurrence were considered for the non-parametric esti-
mation of disease-free survival using the Kaplan-Meier
method. Risk curves were used, and comparisons were
performed using the log-rank test and the Cox hazard
model, considering p-values ≤0.05. In multiple Cox ana-
lysis, each clinical variable, such as molecular subtype,
TNM and histology (ductal and lobular), was compared
separately with the miRNA expression. The survival R
package was used in this analysis [31].
Tissue microarray analysis
Considering that the three selected miRNAs shared PTEN
as target we performed a tissue microarray analysis of
these 64 cases of breast cancer, in duplicate, to evaluate
the expression of this protein in both group of patients
(metastatic and metastatic breast cancer). The TMAs were
assembled using a manual tissue microarrayer (Beecher
Instruments, Silver Springs, MD - USA). The TMA was
done, with control tissues (testis and placenta tissue) and a
series of 64 duplicate samples of breast ductal carcinoma
and lobular histology were related to clinical stage I, II and
III the same samples used in the screening by microarray,
totaling 128 points in the receptor block.
Sections of 5 μm were cut from the TMA and further
processed to immunostaning with PTEN antibody. For the
immunohistochemistry of PTEN a Cell Signaling Mono-
clonal (reference number 9551P) antibody was used,
diluted 1:250. Deparaffinised formalin-fixed, paraffin-
embedded tissue sections were heated in the pretreat-
ment module of the autostainer in Tris–HCl pH 8.5
buffer (for 20 minutes at 98°C). To detect the immune
reaction we used the sequential system with peroxidase-
conjugated secondary antibody (Abcam, USA) or the
amplification system SS polymer Polymer Volume
Mega-HRP Detection Kit (BioGenex, USA) according to
the manufacturer's specifications. For the development
of the tags the chromogen diaminobenzidine, DAB
(Sigma, USA) and counter-stained with hematoxylin
was used. Images of histological sections were digitized
using Eclipse 50i microscope (Nikon, Japan) coupled to
a digital video camera Sight DS system - Fi1 (Nikon,
Japan) with an image analyzer Image-Pro Express
version 6.0 (Media Cybernetics, USA).
Functional analysis
Target prediction was performed using the mirDIP inter-
face [32]. In the present search, we selected at least 3 of
12 algorithms available for prediction. The targets were
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Annotation, Visualization and Integrated Discovery (DA-
VID) version 6.7 [33,34]. This approach was used to
identify significant biological processes and pathways
that could be shared between targets of miRNAs of
interest. A biological process or pathway was considered
significant if it contained a minimum of 3 genes per cat-
egory, featuring score values less than 0.05 including the
Benjamini-Hochberg correction.
Results
The present study included 64 breast cancer patients, in-
cluding non-metastatic patients (n = 35) and those with
metastatic recurrence or metastasis at follow up (n = 29).
The groups were stratified according to clinical staging
(CS) as CSI, CSII and CSIII with the intention of identi-
fying specific and shared miRNAs associated with me-
tastasis. There were no differences between the groups
before pairing with regard to CS; after pairing, the only
difference between the groups was related to PR status
(p = 0.02; Table 1).
miRNAs differentially expressed between non-metastatic
and metastatic patients
The differentially expressed miRNAs (non-metastatic vs.
metastatic groups) stratified according to clinical stage
(CSI, CSII and CSIII) are shown in Additional file 2:
Figure S1. The optimal biomarkers were ranked accord-
ing to sensitivity and specificity values ≥ 80%. The clus-
ters resulting from this analysis are represented in
Figure 1, revealing miRNAs highly specific for the meta-
static process. The miRNA hsa-miR-183 (CSII) was also
selected for further analysis.
Seven microRNAs were identified in the metastatic
group irrespective of clinical staging (hsa-let-7a, hsa-let-
7b, hsa-let-7c, hsa-miR-1308, hsa-miR-21, hsa-miR-494
and hsa-miR-923_v12.0, Figure 2). Of these, hsa-miR-
494 and hsa-miR-21 were selected for further analysis
using real-time PCR.
Relative risk analysis
The miRNA expression levels of the 64 patients evalu-
ated in the microarray were assessed using real-time
PCR for relative risk analysis. The primers used are
shown in Additional file 3: Table S1.
The 3 microRNAs selected for further real-time PCR
analysis shared important biological features, especially
with regard to phosphoprotein- and kinase protein-
associated functions, according to functional analysis.
The ROC curve, considering the non-metastatic group
as the reference, was used to select the threshold value for
miRNA modulation of quantitative values obtained by
real-time PCR. The values for the area under the curve
(AUC), sensitivity and specificity are presented in Table 2.The relative risk curves using recurrence data as events
are shown in Figure 3. Because of the small number of
CSI patients, it was not possible to perform this analysis
for this group. For CSII patients, hsa-miR-183 was the
only miRNA that was significant when analyzed independ-
ently using the log-rank test (p = 0.03). In contrast, hsa-
miR-21 and hsa-miR-494 showed no significance (p = 0.88
and 0.86, respectively). After combining the up-regulated
levels of these 3 miRNAs our analysis, showed that were
associated with metastatic events (p = 0.002). The combin-
ation of hsa-miR-21 with hsa-miR-494 was not significant
after the log-rank test (p = 0.123), whereas other combina-
tions such as hsa-miR-21 with hsa-miR-183 (p = 0.004)
and hsa-miR-183 with hsa-miR-494 (p = 0.001) were
significant. Among CSIII cases, we did not find signifi-
cant results (data not shown). The miRNA expression
and clinical variable data were included in the multiple
Cox models, and the best results are shown in Table 3.
The main characteristics that provided some degree of
risk included lobular histology, T2, N1 and the Her2
molecular subtype. However, none of these factors were
significant in CSII patients and miRNA expression was a
more effective independent prognostic factor in all cases.
Finally, our results showed that PTEN protein could
not be detected in almost all cases of breast cancer sam-
ples when the three miRNAs were induced by TMA
methodology (Figure 4).
Discussion
Despite recent findings regarding the role of microRNAs
in metastasis, the molecular mechanisms of breast
cancer progression remain incompletely understood. For
example, the prognostic significance of tumor grade in
this type of cancer remains unknown, as well as the
molecular mechanisms for why small tumors from CSI
(as well as those from CSII and CSIII) can lead to metas-
tasis, which presented 10-years of follow-up. The CSI
metastatic samples are extremely rare to obtain, and, in
the present study it was possible to obtain four cases in
hundreds of patients analyzed. Although there were
difficulties associated with obtaining sufficient numbers
of CSI metastatic samples, the similarities between
tumors of different clinical stages were considered. We
performed a retrospective study and identified new bio-
markers of breast cancer metastasis that are both shared
and specific to clinical stages I-III using FFPE samples.
Despite low quality of FFPE samples, several studies
have showed the stability of miRNAs [7,8], because may
be less affected than mRNA by formalin fixation and
paraffin embedding perhaps due to their smaller size
and lack of poly A tails [35]. In the present study, an
additional quality control was performed, showing high
correlation of frozen samples and FFPE samples used
(Additional file 1: Figure S2).
Figure 1 Heatmaps of the best biomarkers stratified according to clinical stage. Figure 1A shows non-metastatic vs. metastatic patients in
CSI, Figure 1B shows patients in CSII, and Figure 1C shows patients in CSIII.
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Figure 2 Venn diagram showing the differentially expressed genes after rank product analysis between CSI, CSII and CSIII non-metastatic
and metastatic paired groups. Figure 2A shows the 7 genes shared between all analyses are represented and Figure 2B shows the best
biomarkers according to sensitivity and specificity values (≥ 80%). The miRNAs selected for real-time PCR confirmation are highlighted in red.
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pression profiling analysis to the study of breast cancer
consisted of disease assessment at the molecular level.
In addition, class-prediction studies aim to identify
miRNA predictors that could be applicable to all pa-
tients with breast cancer, with the goal of separating
patients according to prognosis and selecting candidate
genes for metastasis during follow up [36].
The Mamaprint, Oncotype DX and Breast Cancer Index
selected patients who were ER positive, and the Veridez
76-gene study evaluated patients without lymph node
metastases [37]. The present case cohort study eva-
luated patients with invasive breast cancer based on
metastasis development and selected microRNAs related
to metastasis development independent of lymph node or
hormonal status.
The Oncotype DX study initially evaluated a retrospect-
ive cohort, and the genes of interest were selected using a
univariate Cox analysis with a median of 15.1 years of
follow up [38]. The Mamaprint study evaluated the odds
of developing distant metastases after a 5-year follow-up
period [39]. We performed a case cohort study with a
control group that had a median follow-up duration ofTable 2 ROC curve analysis for real-time PCR threshold value
microRNA Threshold value
miR-21 1.89
miR-183 4.708
miR-494 1.688
miR-21 +miR-494 0.497
miR-21 +miR-183 0.431
miR-183 +miR-494 0.354
miR-183 +miR-21 +miR-494 0.56710 years, which decreased the bias related to patient class
migration.
The main prognostic factors related to breast cancer
are summarized according to the TNM classification;
therefore, at diagnosis, the tumor size, lymph node sta-
tus and distant metastases represent the main prognostic
factors. Another independent prognostic factor is the
gene signature; however, this is not easy to evaluate in
clinical practice. Although a semi-quantitative assess-
ment of ER, PR, HER2 and Ki67 status-using immuno-
histochemistry is frequently used in clinical practice, this
method does not provide the true gene signature [39].
In our study, we standardized the cases and controls
according to TNM classification that is considered the
main breast cancer prognostic factor and we did not
observe any differences between the groups (Table 1).
Other variables included in the analysis were related
to histology and immunohistochemistry markers.
Although the PR status was different between the
groups, this did not serve as a prognostic factor, which
may be due to the limited number of patients evalu-
ated or a possible bias associated with the group
selection.determination of miRNAs in CSII patients
AUC Sensitivity (%) Specificity (%)
0.438 30 75
0.769 75 80
0.400 30 75
0.600 50 75
0.823 90 70
0.830 70 75
0.838 75 80
Figure 3 Relative risk curves of the best biomarkers in CSII patients. In A, B and C, miRNAs miR-21, miR-183 and miR-494 were analyzed
separately. In D, the combination of miR-21 and miR-183 was analyzed. In E, the combination of miR-21 and miR-494 was analyzed. In F, the
miR-183 and miR-494 combination was analyzed. In G, the combination of the three miRNAs studied (miR-21, miR-183 and miR-494). The miRNA
up-regulation is represent by dotted lines, and down-regulation is represented by a continuous line.
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metastasis, Valastyan [15] reviewed the role of micro-
RNAs according to the steps of the metastatic cascade.
In our study, miRNAs shared by clinical stages I-III were
found in concordance with processes such as cell motil-
ity (let-7 family) and distant metastases (hsa-miR-21). Ofthese miRNAs, we chose to confirm hsa-miR-21 using
real-time PCR because it is the most frequently reported
miRNA in several types of solid cancers, representing a
potential oncomir [40,41].
These miRNAs have been described as regulating
oncogenes or tumor suppressor genes. The let-7 family
Table 3 Cox hazard models used in combination with
hsa-miR-21, hsa-miR-494 and hsa-miR-183 in CSII patients
Covariate Category HR (95% CI) p value
Histology Ductal 1 0.1105
Lobular 3.374 (0.7577-15.02)
miRNA regulation Down 1 0.0134
Up 5.8382 (1.44192-23.64)
T-TNM Other 1 0.41401
T2 1.7449 (0.4589-6.635)
miRNA regulation Down 1 0.00604
Up 7.584 (1.7856-32.207)
N-TNM N0 1 0.30875
N1 2.009 (0.5244-7.695)
miRNA regulation Down 1 0.00733
Up 6.6417 (1.664-26.503)
Molecular subtype Other 1 0.08739
Her2 3.766 (0.8233-17.23)
miRNA regulation Down 1 0.00528
Up 8.332 (1.8785-36.95)
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in breast cancer cells and is associated with several
mechanisms of carcinogenesis, including EMT [42,43].
The other microRNA differentially expressed in both
clinical staging, hsa-miR-494, targets several molecules
relevant to cancer, including PTEN [44]. Transfection
studies have shown this miRNA to act as a master
cell cycle regulator at the G1/S checkpoint by targeting
CDK6 [45] and at G2/M arrest by targeting PLK1,
PTTG1, CCNB1, CDC2, CDC20 and TOP2A [46], and
this miRNA also affects cell proliferation in A549 lung
cells by regulating IGFBP1 and IGF2 [47] and in gastro-
intestinal tumor cells by direct targeting KIT [48]. In
addition, miR-494 also appears to have a role in TRAIL-
induced apoptosis [49] as well as the immune system
via its regulation of key transcription factors, such as
interferon ɣ and TGFβ1 [50]. The evidence of its role in
metastasis was demonstrated as an exossomal miRNA
in pre-metastatic sites targeting cadherin-17 in mice
[51]. Together, these data as well as the findings of the
present study highlight this miRNA as a new interesting
candidate for verification in metastatic breast cancer.SII
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21 and miR-494, both confirmed by RT-qPCR in all CS.
However, it was not clear the sensitivity and specificity
of these biomarkers. After ROC curve analysis, despite
the miR-21 was found as differentially expressed in all CS,
only presented AUC ≥ 80% in CSI-CSIM and miR-494
were not significative. For these reasons, we also selected
other miRNAs of CSII and CSIII to improve the sensibility
and specificity.
Supervised analysis, based on clinical staging stratifica-
tion, identified hsa-miR-183 as the best microRNA with
regard to sensitivity and specificity in CSII (Figure 2).
The hsa-miR-140-3p, the miRNA tested for CSIII, did
not confirm microarray results (data not shown). Of
these stage-specific microRNAs, miR-183, which was
specific to CSII, is considered an oncogene because it
targets DKK3, SMAD4, EGR1, PTEN and the PI3K path-
way, and it is frequently described in breast cancer as
well as other reproductive system related-cancers such
as prostate, ovarian and urothelial carcinomas [52,53].
Moreover, miR-183 has been considered a metastatic
inhibitor by targeting ezrin [53] and lymph node metas-
tasis in medullary thyroid carcinoma [54], and this
miRNA was recently described as being involved in
breast cancer progression [55]. Despite these findings,
our study is the first to report the association between
miR-183 and CSII patients.
Despite the fact that microRNAs hsa-miR-494 and
hsa-miR-21 share important targets such as PTEN, this
combination was not significant after the log-rank test
for CSII or all clinical stages pooled together (data not
shown). These miRNAs presented an increased risk only
when they were analyzed in combination with miR-183.
Moreover, in regards to the molecular mechanisms
shared by targets of these miRNAs, we identified phos-
phoproteins, specifically kinases, among both miRNA
targets. For example, KIT and BCL6 were among the
hsa-miR-494 proto-oncogenic targets, which represented
a significant category with 34 genes, whereas tumor sup-
pressors and apoptotic genes were more evident among
hsa-miR-183 target genes, including PTEN, PDCD4 and
BCL10, as well as tyrosine kinase signaling pathways.
Protein expression of PTEN by TMA analysis showed
no differences between metastatic and non metastatic
breast tumors (Figure 4). The results showed that
expression of PTEN protein was repressed in all cases
of breast cancer while the three microRNAs are in-
duced. Considering that some spots of TMA was lost,
specially to CSI non metastatic tumor samples, probably
this could be a limitation to see differences between meta-
static group versus non metastatic group about the this
protein expression. In our concern further studies using
functional assays can be design to better explain the role
of these microRNAs in PTEN regulation.The 3 miRNAs selected (hsa-miR-21, hsa-miR-494
and hsa-miR-183) share PTEN as a target, and this com-
bination demonstrated an increased risk for metastasis
(Figure 3), which suggests some potentially shared
mechanism of action. Moreover, the Cox regression
analysis showed that the risk of breast cancer metastasis
was more likely to be related to miRNA expression and
appeared to be independent of clinic pathological vari-
ables. In this study, a homogeneous population was
intentionally selected to evaluate the effect of miRNA
deregulation with increased efficacy. However, it will be
necessary to perform further studies in larger popula-
tions to validate these findings. Together, our findings
indicate that miRNAs can be independently associated
with patient prognosis in breast cancer and may repre-
sent risk biomarkers for the development of breast
cancer metastasis.
Further studies are necessary to understand the role
of these new candidate risk biomarkers and the effects
of the combination of these miRNAs in breast cancer
metastasis, especially in CSII.
Conclusions
Taken together, we demonstrate that miR-183, miR-494
and miR-21 were up-regulated in metastatic breast cancer
tissues that was associated a poor prognosis. The TMA
analysis showed that the expression of PTEN protein was
repressed in all cases of breast cancer while the three miR-
NAs are induced. These data can indicate that these miR-
NAs represent new risk biomarkers of metastatic breast
cancer and may be useful for future targeted studies.
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